Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Can Fite BiopharmaCANF +1.27%60 3-Year Share Buyback Ratio is -112.70 as of Dec. 2025. GuruFocus rates CANF with a GF Score™ of 60/100 and a GF Value™ of $5.94 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,194 Biotechnology companies, Can Fite Biopharma ranks worse than 92.21% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Can Fite Biopharma's current 3-Year Share Buyback Ratio was -112.70%.
The historical rank and industry rank for Can Fite Biopharma's 3-Year Share Buyback Ratio or its related term are showing as below:
CANF'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -175.6 Med: -43 Max: -13
Current: -112.7
During the past 13 years, Can Fite Biopharma's highest 3-Year Share Buyback Ratio was -13.00%. The lowest was -175.60%. And the median was -43.00%.
CANF's 3-Year Share Buyback Ratio is ranked worse than 92.21% of 1194
companies
in the Biotechnology industry
Industry Median: -11.65
vs CANF: -112.70
Can Fite Biopharma (AMEX:CANF) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Can Fite Biopharma 3-Year Share Buyback Ratio Related Terms
CANF vs VRTX, REGN, RVMD: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Can Fite Biopharma's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's 3-Year Share Buyback Ratio falls into.
Can Fite Biopharma 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -112.70 mean?
Can Fite Biopharma (CANF) has a 3-Year Share Buyback Ratio of -112.70 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Can Fite Biopharma and its competitors. According to the industry distribution chart, Can Fite Biopharma ranks #1101 out of 1194 companies in the Biotechnology industry, placing it in the top 92.2%.
Is Can Fite Biopharma's 3-Year Share Buyback Ratio too high?
Can Fite Biopharma's current 3-Year Share Buyback Ratio is -112.70. Based on the distribution chart, Can Fite Biopharma ranks #1101 out of 1194 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Can Fite Biopharma has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's 3-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #1101 out of 1194 companies for 3-Year Share Buyback Ratio. This places Can Fite Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Can Fite Biopharma and its competitors. Can Fite Biopharma's current 3-Year Share Buyback Ratio is -112.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Possible Value Trap. The stock's GF Value™ is $5.94, compared to a current price of $3.20 — trading 46.1% below its estimated fair value. The current 3-Year Share Buyback Ratio is -112.70. Can Fite Biopharma's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current 3-Year Share Buyback Ratio is -112.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of $3.20 is trading 46.1% below its estimated GF Value™ of $5.94.
GuruFocus considers Can Fite Biopharma to be Possible Value Trap.
Key valuation signals for CANF:
3-Year Share Buyback Ratio: -112.70
GF Value™: $5.94 vs. price of $3.20 (46.1% below fair value)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
60GF Score
Get the complete analysis for CANF
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
